Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peg-erythropoietin
- Development stage
- Unknown
- Lead developer
- Pooyesh Darou
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
Peg-erythropoietin (marketed as Perythro) is a PEGylated recombinant human erythropoietin (rhEPO) developed by the Iranian biotechnology company Pooyesh Darou. As a biosimilar of methoxy polyethylene glycol-epoetin beta (Mircera), it consists of an erythropoietin protein covalently linked to a polyethylene glycol (PEG) polymer. This modification significantly extends the drug's half-life, allowing for a reduced dosing frequency (typically once every two to four weeks) compared to non-PEGylated erythropoiesis-stimulating agents. Peg-erythropoietin acts as an agonist of the erythropoietin receptor (EPOR), stimulating the production of red blood cells in the bone marrow. It is approved and marketed for the treatment of anemia associated with chronic kidney disease (CKD) in both dialysis and non-dialysis patients.
- Brand names
- Perythro
- Other names
- peg-erythropoietinPEG-EPOPEG-rhEPOPEGylated recombinant human erythropoietin
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on peg-erythropoietin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peg-erythropoietin.